Trending
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Capital, M&A & Industry Strategy6 hours agoFDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed...
-
Global Biotechnology & Pharmaceutical Markets11 hours agoWCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability...
-
Global Biotechnology & Pharmaceutical Markets11 hours agoEnsuring safety and accountability in China’s biomedical translation system
Nature Biotechnology, Published online: 15 September 2026; doi:10.1038/s41587-026-03314-xChina’s Decree 818 aims to bring hospital-based cell, gene and individualized therapies into the clinic safely. Its success will...
-
Helixgate Featured13 hours agoFDA launches pilot program to speed up early US drug research
First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines...
-
Regulatory Intelligence & Drug Approvals13 hours agoSTAT+: Obesity drugmakers are testing in kids as young as 6
Vera seeks kidney drug approval, early data from Syntis Bio, and other biotech news from The Readout
-
Clinical Trials & Development13 hours agoFDA launches pilot program to speed up sluggish phase 1 trials
After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program for an expedited investigational new...
-
Clinical Trials & Development17 hours agoSTAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
The drug stabilized kidney function and reduced the risk of death and other complications in IgAN patients
-
Clinical Trials & Development17 hours ago
Connect’s Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.
-
Capital, M&A & Industry Strategy17 hours agoCheplapharm to take over 20 medicines and three sites from Sanofi
Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began...
-
Regulatory Intelligence & Drug Approvals18 hours agoFDA reduces monitoring time for Amgen’s Imdelltra infusions
The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy. It recommends a monitoring period ranging between six and eight...
